{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T09:01:00Z","timestamp":1721120460604},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["SFRH\/BD\/71397\/2010","SFRH\/BD\/73719\/2010"],"award-info":[{"award-number":["SFRH\/BD\/71397\/2010","SFRH\/BD\/73719\/2010"]}]},{"name":"Liga Portuguesa Contra o Cancro, N\u00facleo Regional do Norte"},{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"crossref","award":["CI-IPOP 16-2012"],"award-info":[{"award-number":["CI-IPOP 16-2012"]}],"id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10689-015-9832-x","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T14:31:53Z","timestamp":1439994713000},"page":"111-121","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The role of germline mutations in the BRCA1\/2 and mismatch repair genes in men ascertained for early-onset and\/or familial prostate cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Sofia","family":"Maia","sequence":"first","affiliation":[]},{"given":"Marta","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Paulo","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"9832_CR1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM, Ray AM, Lange EM et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141\u2013149. doi: 10.1056\/NEJMoa1110000","journal-title":"N Engl J Med"},{"key":"9832_CR2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djs288","volume":"104","author":"MR Akbari","year":"2012","unstructured":"Akbari MR, Trachtenberg J, Lee J et al (2012) Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 104:1260\u20131262. doi: 10.1093\/jnci\/djs288","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR3","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-12-0495","volume":"21","author":"JP Breyer","year":"2012","unstructured":"Breyer JP, Avritt TG, McReynolds KM et al (2012) Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomark Prev 21:1348\u20131353. doi: 10.1158\/1055-9965.EPI-12-0495","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1055-9965.EPI-12-1000-T","volume":"22","author":"VH Laitinen","year":"2013","unstructured":"Laitinen VH, Wahlfors T, Saaristo L et al (2013) HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomark Prev 22:452\u2013460. doi: 10.1158\/1055-9965.EPI-12-1000-T","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","volume":"132","author":"J Xu","year":"2013","unstructured":"Xu J, Lange EM, Lu L et al (2013) HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 132:5\u201314. doi: 10.1007\/s00439-012-1229-4","journal-title":"Hum Genet"},{"key":"9832_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","volume":"65","author":"R Karlsson","year":"2014","unstructured":"Karlsson R, Aly M, Clements M et al (2014) A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 65:169\u2013176. doi: 10.1016\/j.eururo.2012.07.027","journal-title":"Eur Urol"},{"key":"9832_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pros.22552","volume":"73","author":"X Lin","year":"2013","unstructured":"Lin X, Qu L, Chen Z et al (2013) A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 73:169\u2013175. doi: 10.1002\/pros.22552","journal-title":"Prostate"},{"key":"9832_CR8","doi-asserted-by":"crossref","first-page":"e0132728","DOI":"10.1371\/journal.pone.0132728","volume":"10","author":"S Maia","year":"2015","unstructured":"Maia S, Cardoso M, Pinto P et al (2015) Identification of two novel HOXB13 germline mutations in portuguese prostate cancer patients. PLoS One 10:e0132728. doi: 10.1371\/journal.pone.0132728","journal-title":"PLoS One"},{"key":"9832_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66\u201371","journal-title":"Science"},{"key":"9832_CR10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1996","unstructured":"Wooster R, Bignell G, Lancaster J et al (1996) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789\u2013792. doi: 10.1038\/378789a0","journal-title":"Nature"},{"key":"9832_CR11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5","volume":"34","author":"EU Thiessen","year":"1974","unstructured":"Thiessen EU (1974) Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 34:1102\u20131107","journal-title":"Cancer"},{"key":"9832_CR12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jnci\/84.14.1114","volume":"84","author":"DE Anderson","year":"1992","unstructured":"Anderson DE, Badzioch MD (1992) Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 84:1114\u20131117","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bmj.305.6858.855","volume":"305","author":"H Tulinius","year":"1992","unstructured":"Tulinius H, Egilsson V, Olafsd\u00f3ttir GH, Sigvaldason H (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 305:855\u2013857. doi: 10.1136\/bmj.305.6858.855","journal-title":"BMJ"},{"key":"9832_CR14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"The Breast Cancer Linkage, Consortium","year":"1999","unstructured":"The Breast Cancer Linkage, Consortium (1999) Cancer risks in BRCA2 mutation carriers. the Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310\u20131316. doi: 10.1093\/jnci\/91.15.1310","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","volume":"42","author":"CJ Asperen Van","year":"2005","unstructured":"Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711\u2013719. doi: 10.1136\/jmg.2004.028829","journal-title":"J Med Genet"},{"key":"9832_CR16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","volume":"105","author":"Z Kote-Jarai","year":"2011","unstructured":"Kote-Jarai Z, Leongamornlert D, Saunders E et al (2011) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105:1230\u20131234. doi: 10.1038\/bjc.2011.383","journal-title":"Br J Cancer"},{"key":"9832_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/345310","volume":"72","author":"SM Edwards","year":"2003","unstructured":"Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1\u201312. doi: 10.1086\/345310","journal-title":"Am J Hum Genet"},{"key":"9832_CR18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert D, Mahmud N, Tymrakiewicz M et al (2012) Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106:1697\u20131701. doi: 10.1038\/bjc.2012.146","journal-title":"Br J Cancer"},{"key":"9832_CR19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CEJ.0b013e32809b4d20","volume":"17","author":"C Cybulski","year":"2008","unstructured":"Cybulski C, G\u00f3rski B, Gronwald J et al (2008) BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 17:62\u201366. doi: 10.1097\/CEJ.0b013e32809b4d20","journal-title":"Eur J Cancer Prev"},{"key":"9832_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","volume":"11","author":"A Moran","year":"2012","unstructured":"Moran A, O\u2019Hara C, Khan S et al (2012) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11:235\u2013242. doi: 10.1007\/s10689-011-9506-2","journal-title":"Fam Cancer"},{"key":"9832_CR21","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1055-9965.EPI-09-0058","volume":"18","author":"EM Grindedal","year":"2009","unstructured":"Grindedal EM, M\u00f8ller P, Eeles R et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomark Prev 18:2460\u20132467. doi: 10.1158\/1055-9965.EPI-09-0058","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR22","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","volume":"30","author":"C Engel","year":"2012","unstructured":"Engel C, Loeffler M, Steinke V et al (2012) Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 30:4409\u20134415. doi: 10.1200\/JCO.2012.43.2278","journal-title":"J Clin Oncol"},{"key":"9832_CR23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/jnci\/djs351","volume":"104","author":"A Win","year":"2012","unstructured":"Win A, Lindor N, Young J et al (2012) Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 104:1363\u20131372. doi: 10.1016\/j.urolonc.2013.03.013","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10689-014-9744-1","volume":"13","author":"C Rosty","year":"2014","unstructured":"Rosty C, Walsh MD, Lindor NM et al (2014) High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam Cancer 13:573\u2013582. doi: 10.1007\/s10689-014-9744-1","journal-title":"Fam Cancer"},{"key":"9832_CR25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","volume":"81","author":"M Aarnio","year":"1999","unstructured":"Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214\u2013218","journal-title":"Int J Cancer"},{"key":"9832_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1086\/316942","volume":"68","author":"RJ Scott","year":"2001","unstructured":"Scott RJ, McPhillips M, Meldrum CJ et al (2001) Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 68:118\u2013127. doi: 10.1086\/316942","journal-title":"Am J Hum Genet"},{"key":"9832_CR27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/humu.22262","volume":"34","author":"JG Dowty","year":"2013","unstructured":"Dowty JG, Win AK, Buchanan DD et al (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34:490\u2013497. doi: 10.1002\/humu.22262","journal-title":"Hum Mutat"},{"key":"9832_CR28","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.2006.06.9443","volume":"25","author":"PM Machado","year":"2007","unstructured":"Machado PM, Brand\u00e3o RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast\/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027\u20132034. doi: 10.1200\/JCO.2006.06.9443","journal-title":"J Clin Oncol"},{"key":"9832_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-008-9978-4","volume":"114","author":"A Peixoto","year":"2009","unstructured":"Peixoto A, Santos C, Rocha P et al (2009) The c.156-157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern\/central Portugal. Breast Cancer Res Treat 114:31\u201338. doi: 10.1007\/s10549-008-9978-4","journal-title":"Breast Cancer Res Treat"},{"key":"9832_CR30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/GIM.0b013e31821dd525","volume":"13","author":"M Pinheiro","year":"2011","unstructured":"Pinheiro M, Pinto C, Peixoto A et al (2011) A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. Genet Med 13:895\u2013902. doi: 10.1097\/GIM.0b013e31821dd525","journal-title":"Genet Med"},{"key":"9832_CR31","doi-asserted-by":"crossref","first-page":"L23","DOI":"10.1530\/ERC-12-0399","volume":"20","author":"RG Martins","year":"2013","unstructured":"Martins RG, Nunes JB, M\u00e1ximo V et al (2013) A founder SDHB mutation in Portuguese paraganglioma patients. Endocr Relat Cancer 20:L23\u2013L26. doi: 10.1530\/ERC-12-0399","journal-title":"Endocr Relat Cancer"},{"key":"9832_CR32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cge.12062","volume":"84","author":"M Pinheiro","year":"2013","unstructured":"Pinheiro M, Pinto C, Peixoto A et al (2013) The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. Clin Genet 84:244\u2013250. doi: 10.1111\/cge.12062","journal-title":"Clin Genet"},{"key":"9832_CR33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/cge.12441","volume":"88","author":"A Peixoto","year":"2014","unstructured":"Peixoto A, Santos C, Pinto P et al (2014) The role of targeted BRCA1\/BRCA2 mutation analysis in hereditary breast\/ovarian cancer families of Portuguese ancestry. Clin Genet 88:41\u201348. doi: 10.1111\/cge.12441","journal-title":"Clin Genet"},{"key":"9832_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ng.2854","volume":"46","author":"BA Thompson","year":"2014","unstructured":"Thompson BA, Spurdle AB, Plazzer JP et al (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107\u2013115. doi: 10.1038\/ng.2854","journal-title":"Nat Genet"},{"key":"9832_CR35","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I et al (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinform. doi: 10.1186\/1471-2105-13-134","journal-title":"BMC Bioinform"},{"key":"9832_CR36","author":"M Pinheiro","year":"2010","unstructured":"Pinheiro M, Ahlquist T, Danielsen SA et al (2010) Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer. doi: 10.1186\/1471-2407-10-587","journal-title":"BMC Cancer"},{"key":"9832_CR37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E et al (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66:489\u2013499. doi: 10.1016\/j.eururo.2014.01.003","journal-title":"Eur Urol"},{"key":"9832_CR38","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.bjc.6603929","volume":"97","author":"I Agalliu","year":"2007","unstructured":"Agalliu I, Karlins E, Kwon EM et al (2007) Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 97:826\u2013831. doi: 10.1038\/sj.bjc.6603929","journal-title":"Br J Cancer"},{"key":"9832_CR39","first-page":"4513","volume":"60","author":"SA Gayther","year":"2000","unstructured":"Gayther SA, de Foy KA, Harrington P et al (2000) The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign\/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60:4513\u20134518","journal-title":"Cancer Res"},{"key":"9832_CR40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F","volume":"39","author":"EP Wilkens","year":"1999","unstructured":"Wilkens EP, Freije D, Xu J et al (1999) No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 39:280\u2013284. doi: 10.1002\/(SICI)1097-0045(19990601)39:4<280:AID-PROS8>3.0.CO;2-F","journal-title":"Prostate"},{"key":"9832_CR41","first-page":"1371","volume":"60","author":"CS Sinclair","year":"2000","unstructured":"Sinclair CS, Berry R, Schaid D et al (2000) BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60:1371\u20131375","journal-title":"Cancer Res"},{"key":"9832_CR42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-06-2164","volume":"13","author":"I Agalliu","year":"2007","unstructured":"Agalliu I, Kwon EM, Zadory D et al (2007) Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 13:839\u2013843. doi: 10.1158\/1078-0432.CCR-06-2164","journal-title":"Clin Cancer Res"},{"key":"9832_CR43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bjc.1998.576","volume":"78","author":"S Lehrer","year":"1998","unstructured":"Lehrer S, Fodor F, Stock RG et al (1998) Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 78:771\u2013773","journal-title":"Br J Cancer"},{"key":"9832_CR44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1086\/302525","volume":"65","author":"A Hubert","year":"1999","unstructured":"Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1\/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921\u2013924. doi: 10.1086\/302525","journal-title":"Am J Hum Genet"},{"key":"9832_CR45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0045(19990801)40:3<172::AID-PROS5>3.0.CO;2-R","volume":"40","author":"KL Nastiuk","year":"1999","unstructured":"Nastiuk KL, Mansukhani M, Terry MB et al (1999) Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40:172\u2013177. doi: 10.1002\/(SICI)1097-0045(19990801)40:3<172:AID-PROS5>3.0.CO;2-R","journal-title":"Prostate"},{"key":"9832_CR46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1054\/bjoc.2000.1249","volume":"83","author":"A Vazina","year":"2000","unstructured":"Vazina A, Baniel J, Yaacobi Y et al (2000) The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463\u2013466. doi: 10.1054\/bjoc.2000.1249","journal-title":"Br J Cancer"},{"key":"9832_CR47","author":"N Hamel","year":"2003","unstructured":"Hamel N, Kotar K, Foulkes WD (2003) Founder mutations in BRCA1\/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet. doi: 10.1186\/1471-2350-4-7","journal-title":"BMC Med Genet"},{"key":"9832_CR48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","volume":"68","author":"D Thompson","year":"2001","unstructured":"Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410\u2013419. doi: 10.1086\/318181","journal-title":"Am J Hum Genet"},{"key":"9832_CR49","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F et al (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313:1347\u20131361. doi: 10.1001\/jama.2014.5985","journal-title":"JAMA"},{"key":"9832_CR50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10689-012-9573-z","volume":"12","author":"PJ Barrow","year":"2013","unstructured":"Barrow PJ, Ingham S, O\u2019Hara C et al (2013) The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 12:57\u201363. doi: 10.1007\/s10689-012-9573-z","journal-title":"Fam Cancer"},{"key":"9832_CR51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","volume":"31","author":"VM Raymond","year":"2013","unstructured":"Raymond VM, Mukherjee B, Wang F et al (2013) Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 31:1713\u20131718. doi: 10.1200\/JCO.2012.44.1238","journal-title":"J Clin Oncol"},{"key":"9832_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/gim.2013.193","volume":"16","author":"S Haraldsdottir","year":"2014","unstructured":"Haraldsdottir S, Hampel H, Wei L et al (2014) Prostate cancer incidence in males with Lynch syndrome. Genet Med 16:1\u20135. doi: 10.1038\/gim.2013.193","journal-title":"Genet Med"},{"key":"9832_CR53","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.ejca.2006.04.024","volume":"42","author":"H Fredriksson","year":"2006","unstructured":"Fredriksson H, Ikonen T, Autio V et al (2006) Identification of germline MLH1 alterations in familial prostate cancer. Eur J Cancer 42:2802\u20132806. doi: 10.1016\/j.ejca.2006.04.024","journal-title":"Eur J Cancer"},{"key":"9832_CR54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajmg.a.20106","volume":"121A","author":"C Soravia","year":"2003","unstructured":"Soravia C, van der Klift H, Br\u00fcndler M-A et al (2003) Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 121A:159\u2013162. doi: 10.1002\/ajmg.a.20106","journal-title":"Am J Med Genet A"},{"key":"9832_CR55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10689-010-9388-8","volume":"10","author":"CM Bauer","year":"2011","unstructured":"Bauer CM, Ray AM, Halstead-Nussloch BA et al (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10:37\u201342. doi: 10.1007\/s10689-010-9388-8","journal-title":"Fam Cancer"},{"key":"9832_CR56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","volume":"185","author":"SE Eggener","year":"2011","unstructured":"Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869\u2013875. doi: 10.1016\/j.juro.2010.10.057","journal-title":"J Urol"},{"key":"9832_CR57","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117\u20131123. doi: 10.1200\/JCO.2009.26.0133","journal-title":"J Clin Oncol"},{"key":"9832_CR58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","volume":"367","author":"TJ Wilt","year":"2012","unstructured":"Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203\u2013213. doi: 10.1056\/NEJMoa1113162","journal-title":"N Engl J Med"},{"key":"9832_CR59","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748\u20131757. doi: 10.1200\/JCO.2012.43.1882","journal-title":"J Clin Oncol"},{"key":"9832_CR60","author":"E Castro","year":"2014","unstructured":"Castro E, Goh C, Leongamornlert D et al (2014) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. doi: 10.1016\/j.eururo.2014.10.022","journal-title":"Eur Urol"},{"key":"9832_CR61","author":"E Castro","year":"2013","unstructured":"Castro E, Goh CL, Eeles RA (2013) Prostate cancer screening in BRCA and Lynch syndrome mutation carriers. Am Soc Clin Oncol Educ Book. doi: 10.1200\/EdBook_AM.2013.33.e50","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9832_CR62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/humu.9366","volume":"26","author":"E Teugels","year":"2005","unstructured":"Teugels E, De Brakeleer S, Goelen G et al (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284. doi: 10.1002\/humu.9366","journal-title":"Hum Mutat"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-015-9832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-015-9832-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-015-9832-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:41:09Z","timestamp":1589568069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-015-9832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["9832"],"URL":"https:\/\/doi.org\/10.1007\/s10689-015-9832-x","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]}}}